Efficacy and safety of Helicobacter pylori eradication therapy with vonoprazan, clarithromycin, and metronidazole for patients with chronic kidney disease without dialysis

Sue Soichiro0 个研究点目标入组 24 人开始时间: 2020年12月11日最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Patients infected with Helicobacter pylori. Positive patients by Urea breath test, stool Helicobacter pylori antigen test, anti-Helicobacter pylori antibody test (blood), Helicobacter pylori culture, rapid urease test, or histrogical diagnosis of Helicobacter pylori are treated with infected.
•Patients who underwent upper gastrointestinal endoscopy and diagnosed as gastritis, gastric ulcer, duodenal ulcer, gastric MALT lymphoma, after endoscopic treatment for early gastric cancer, or idiopathic thrombocytopenic purpura.
•Patients whose eGFR revel is from 10mL/min/1.73m2 to 45mL/min/1.73m2 at the study entry, and diagnosed as chronic kidney disease.
•Patients who give a written informed consent.

•Patients who have Helicobacter pylori eradication history. Hemodialysis patients for renal failure. Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. Patients using atazanavir, rilpivirine, pimozide, ergotamine, suvorexant, lomitapide mesylate, tadalafil, ticagrelor, ibrutinib, asuna previr, ivavradine, venetoclax, colchicine, lurasidone hydrochloride, anamorelin hydrochloride, finerenone, or isavuconazonium sulfate. A patient with brain and spinal cord disease. Patients who are disqualified for the study by physicians.

发起方

Sue Soichiro